Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. (Q51585133)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 August 2016

Language	Label	Description	Also known as
English	Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.	scientific article published on 8 August 2016

Statements

scholarly article

1 reference

Europe PubMed Central

7 April 2018

http://europepmc.org/abstract/MED/27501474

Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. (English)

1 reference

Europe PubMed Central

7 April 2018

http://europepmc.org/abstract/MED/27501474

chronic myeloid leukemia

0 references

Leylagul Kaynar

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Guray Saydam

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ibrahim Celalettin Haznedaroglu

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Akif S Yavuz

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ridvan Ali

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Birol Guvenc

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Olga M Akay

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Zafer Baslar

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ugur Ozbek

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Mehmet Sonmez

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Demet Aydin

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Mustafa Pehlivan

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Bulent Undar

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Simten Dagdas

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Orhan Ayyildiz

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Diyar Z Akkaynak

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ilkiz M Dag

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Osman Ilhan

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

0 references

publication date

8 August 2016

1 reference

Europe PubMed Central

7 April 2018

http://europepmc.org/abstract/MED/27501474

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1851-1858

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Standardized definitions of molecular response in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Deep molecular response in chronic myeloid leukemia: the new goal of therapy?

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations.

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1219338

21 January 2018

Identifiers

10.1080/14656566.2016.1219338

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27501474%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51585133&oldid=1295285967"